An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or CD30-positive cutaneous T-cell lymphoma

Trial Profile

An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or CD30-positive cutaneous T-cell lymphoma

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions; Expanded access
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 29 Nov 2017 This trial is completed in Germany (end date:2017-03-06).
    • 13 Jul 2016 This trial is completed in Czech Republic and Bulgaria (end date:14 Jan 2013).
    • 03 Aug 2015 The protocol was amended to reflect the change from a phase 2/3 to a study with an expanded access program, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top